RaySearch Laboratories : Interim report January 1 - June 30, 2023
STOCKHOLM, Aug. 25, 2023 /PRNewswire/ -- SECOND QUARTER (APRIL-JUNE 2023)
Order intake SEK 239.2 M (212.5)
Net sales SEK 239.5 M (160.2)
Operating profit SEK 18.2 M (-19.5)
Profit after tax SEK 10.9 M (-19.7)
Earnings per share before/after dilution SEK 0.32 (-0.58)
Cash flow SEK -3.3 M (16.7)
Order backlog SEK 1,954.9 M (1,540.3) at the end of the period
HALF-YEAR (JANUARY-JUNE 2023)
Order intake SEK 445.8 M (485.0)
Net sales SEK 469.6 M (368.4)
Operating profit SEK 41.9 M (10.0)
Profit after tax SEK 28.5 M (-0.4)
Earnings per share before/after dilution SEK 0.83 (-0.01)
Cash flow SEK 81.2 M (52.0)
SIGNIFICANT EVENTS DURING THE SECOND QUARTER
Yonsei Cancer Center, South Korea, treated its first patient using RayStation and RayCare for carbon ion radiation therapy.
New York University Langone Hospital, USA, placed an order for RayStation, which will replace its current treatment planning system.
RaySearch's strategic partnership with BEBIG Medical, Germany, was extended through a new agreement.
RayCare is interoperable with Varian's TrueBeam.
Shinva, a Chinese radiation therapy machine manufacturer, placed an order for 15 RayPlan systems for onwards sales to customers in China.
Australian Bragg Center for Proton Therapy and Research placed an order for RayCare.
South West Florida Proton, USA, placed an order for RayStation.
In June, 800,000 Class A shares were converted to Class B shares. The total number of votes in RaySearch subsequently amounts to 103,177,548. The total number of registered shares in RaySearch amounts to 34,282,773 of which 7,654,975 are Class A shares and 26,627,798 are Class B shares.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
Henrik Bergentoft left the position as CFO. Annika Blondeau Henriksson was appointed interim CFO.
University Medical Center Groningen, the Netherlands, placed an order for Micro-RayStation for pre-clinical research.
RayCare is in clinical use with CyberKnife at Lausanne University Hospital, Switzerland.
The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 25, 2023 at 7:45 a.m. CEST.
WEBCAST
CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January -June 2023 at a webcast to be held in English on Friday, August 25, 2023 at 10:00-10:30 a.m. CEST.
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community. Aspire Health experienced a data security incident that may have involved personal and...